How should patients with chronic liver disease (cirrhosis) be screened for esophageal varices using upper endoscopy (EGD), including timing, repeat intervals, and primary prophylaxis recommendations?

Screening Endoscopy for Esophageal Varices in Chronic Liver Disease

All patients with newly diagnosed cirrhosis should undergo screening upper endoscopy (EGD) at the time of diagnosis to detect esophageal varices, unless they meet specific non-invasive criteria that safely exclude high-risk varices (liver stiffness <20 kPa and platelet count >150,000/µL). 1

Initial Screening Strategy

Non-Invasive Risk Stratification (Baveno VII Criteria)

The most recent consensus provides clear thresholds to avoid unnecessary endoscopy:

• Patients with liver stiffness <20 kPa AND platelet count >150,000/µL can safely skip screening endoscopy because high-risk varices are effectively excluded 1
• Patients with liver stiffness <12 kPa AND platelet count >150,000/µL have no clinically significant portal hypertension and require no endoscopic assessment whatsoever 1
• Patients with liver stiffness ≥20 kPa OR platelet count <150,000/µL should undergo endoscopy unless already on non-selective beta-blockers 1

When Endoscopy Cannot Be Avoided

Perform screening EGD at diagnosis for: 2

• Patients not meeting the above non-invasive exclusion criteria
• Decompensated cirrhosis patients (they have clinically significant portal hypertension by definition) 2
• Patients with liver stiffness >25 kPa (highly likely to have clinically significant portal hypertension) 1

Common pitfall: Patients already on non-selective beta-blockers (propranolol, nadolol, carvedilol) for other indications (e.g., hypertension) can skip screening endoscopy entirely because they are already receiving prophylaxis. 2 However, those on selective beta-blockers (metoprolol, atenolol) must be switched to non-selective agents. 2

Surveillance Intervals After Initial Screening

The frequency of repeat endoscopy depends on initial findings and disease compensation status:

For Compensated Cirrhosis:

No varices found:

• Repeat EGD every 2-3 years 2
• The 2007 Hepatology guidelines specify 2-3 years 2, while the 2000 British Society of Gastroenterology guidelines recommend 3-year intervals 2
• More frequent surveillance (every 2 years) is warranted if ongoing liver injury persists (active alcohol use, lack of viral cure, obesity) 2

Small varices found:

• Repeat EGD every 1-2 years 2
• The 2000 UK guidelines specifically recommend yearly intervals 2
• More frequent surveillance (yearly) is indicated with ongoing liver injury or cofactors 2

For Decompensated Cirrhosis:

Any variceal finding or no varices:

• Repeat EGD annually (every year) 2, 1
• Decompensated patients have clinically significant portal hypertension by definition and are at higher risk for variceal development and progression 2
• When decompensation develops in a patient previously without varices, repeat endoscopy should be performed promptly 2

Variceal Classification and Documentation

During endoscopy, varices should be classified using a simplified two-grade system: 2

• Small varices: <5 mm diameter, minimally elevated above esophageal mucosa
• Large varices: ≥5 mm diameter or occupying >1/3 of esophageal lumen (when using 3-grade systems, medium and large are grouped together)
• Red signs: Document presence of red wale marks or red spots, which indicate higher bleeding risk 2

Primary Prophylaxis Recommendations

Pharmacological Therapy (First-Line):

For large varices (≥5 mm):

• Non-selective beta-blockers are the best available modality 2
• Propranolol: Start 40 mg twice daily, increase to 80 mg twice daily if needed 2
• Goal: Reduce hepatic venous pressure gradient to <12 mmHg 2
• Long-acting propranolol (80-160 mg daily) can improve compliance 2

For small varices with clinically significant portal hypertension:

• Non-selective beta-blockers are preferred first-line therapy 1
• All patients with clinically significant portal hypertension should receive beta-blockers to prevent both variceal bleeding and non-bleeding decompensation events 1

For grade 2 varices with Child-Pugh B or C disease:

• Primary prophylaxis is indicated 2

For grade 3 varices:

• Primary prophylaxis is indicated regardless of liver disease severity 2

Endoscopic Therapy (Alternative):

Variceal band ligation is the treatment of choice when: 2

• Contraindications to propranolol exist
• Intolerance to propranolol develops
• Patient preference after discussion of options

Isosorbide mononitrate (20 mg twice daily) is reserved for difficult situations where neither propranolol nor band ligation can be used 2

Special Considerations for High-Risk Patients

Patients with liver stiffness >25 kPa:

• Can be started on non-selective beta-blockers empirically without awaiting endoscopic confirmation of varices 1
• Endoscopy may still be performed if variceal status will influence management decisions 1

Patients with liver stiffness 20-25 kPa or platelets <150,000/µL:

• Clinically significant portal hypertension is probable 1
• Endoscopy should be performed if not already on non-selective beta-blockers 1

Key Clinical Pitfalls to Avoid

1. Do not use selective beta-blockers (metoprolol, atenolol) for portal hypertension—they are ineffective. Switch to non-selective agents. 2, 1

2. Do not start beta-blockers in patients without clinically significant portal hypertension—they are ineffective and cause side effects without benefit. 2, 1

3. Do not perform screening endoscopy in patients meeting Baveno VII exclusion criteria (liver stiffness <20 kPa and platelets >150,000/µL)—this is cost-ineffective and exposes patients to unnecessary procedural risks. 1

4. Do not forget to screen decompensated patients—they are deemed high-risk and should have EGD performed unless previously diagnosed and treated. 2

5. Do not delay repeat endoscopy when decompensation develops—this indicates worsening portal hypertension and higher incidence of variceal development. 2